Drug Profile
Abituzumab - Merck Serono
Alternative Names: Anti-CD51 antigen mAb; Anti-integrin alphaV mAb; DI 17E6; EMD525797Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator EMD Serono; Merck Serono
- Developer Merck Serono; SFJ Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- Discontinued Ovarian cancer; Prostate cancer; Solid tumours; Systemic scleroderma
Most Recent Events
- 19 Jul 2022 Phase-II clinical trials in Colorectal cancer in USA (IV) (SFJ Pharmaceuticals pipeline, July 2022)
- 02 May 2018 Merck enters into a agreement with with SFJ Pharmaceuticals to develop abituzumab through a novel risk-sharing collaboration agreement
- 11 Jan 2018 Merck and EMD Serono discontinues phase-II clinical trials in Systemic scleroderma in USA, Spain, United Kingdom, Poland, Italy, Israel, Canada, Australia, Argentina (IV) (NCT02745145)